4th Quarter - Report

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$1,610,710
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988, S. 2123 and H.R. 5771, The Charitable Giving Tax Deduction Act. H.R. 1337, Legacy IRA Act respecting charitable giving and life income planning, and H.R. 6760, the Protecting Family and Small Business Tax Cuts Act of 2018 respecting the medical expense deduction

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE New —

Contacted: White House Office; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); U.S. Agency for International Development (USAID); State, Dept of (DOS); SENATE; U.S. Trade Representative (USTR); Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1337 (115th), S. 2123 (115th), H.R. 3988 (115th), H.R. 5771 (115th), H.R. 6760 (115th)

Health Issues HCR

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; H.R. 4122 & S. 2006, the Breast Density & Mammography Reporting Act; and H.R.820 & S.292, the Childhood Cancer STAR Act. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. The proposed Medical Records Fairness Act (no number yet). Issues regarding the Affordable Care Act premium tax credits and catastrophic plans, HR 6311. Issues regarding protections for people with pre-existing conditions, including S. 3388, HR 6898, and H. Res. 1066. Resolutions to disapprove the short-term rule, H.J. Res 140 and S. J. Res. 63. Advocacy against including the Association Health Plan provision of the House Farm bill in the conference report, H.R. 2 and s. 3042 (section 6004 of the House-passed version of the legislation). Issues involving patient navigation, including the Patient Navigation Assistance Act, HR 6808. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on patient access to medical records. Draft legislation on FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018. H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018. Issues related to caregiving, including H.R. 3759/S. 1028, the RAISE Family Caregivers Act, H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
STEPHANIE KRENRICH —
CAROLINE POWERS —
DENYS C SYMONETTE New —
PHYLICIA L WOODS —

Contacted: Centers For Disease Control & Prevention (CDC); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); Labor, Dept of (DOL); Environmental Protection Agency (EPA); White House Office; Health & Human Services, Dept of (HHS); State, Dept of (DOS); U.S. Trade Representative (USTR); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 497 (115th), H.R. 6808 (115th), H.R. 6311 (115th), H.Res. 1066 (115th), S. 2358 (115th), H.R. 4897 (115th), S. 204 (115th), H.R. 820 (115th), H.R. 930 (115th), H.R. 1676 (115th), S. 693 (115th), S. 2006 (115th), S.J.Res. 63 (115th), H.R. 1028 (115th), S. 3388 (115th), S. 292 (115th), S. 1719 (115th), H.R. 3759 (115th), H.R. 2 (115th), H.Res. 282 (115th), H.R. 4122 (115th), H.R. 6 (115th), H.J.Res. 140 (115th), H.R. 1409 (115th), H.R. 6898 (115th), S. 1028 (115th), H.R. 878 (115th), S. 3042 (115th)

Medicare/Medicaid MMM

Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479 and regulatory issues related to the Medicare coinsurance issue in these bills; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on establishment of Medicaid payment for patient navigation. Issues relating to Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial. Issues related to Medicare coverage for BCRA testing and preventive surgery (proposed Murkowski legislation).

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
STEPHANIE KRENRICH New —
CAROLINE POWERS —
DENYS C SYMONETTE New —
PHYLICIA L WOODS New —

Contacted: U.S. Trade Representative (USTR); Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Labor, Dept of (DOL)

Bills named: S. 479 (115th), H.R. 1017 (115th), H.R. 6 (115th)

Budget/Appropriations BUD

Federal budget and appropriations for cancer research and programs, including: FY 2019 federal appropriations for the FDA; the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the State/Foreign Operations Appropriations Act; issues relating to global health funding for HPV vaccination and cervical cancer screening and treatment: and issues regarding future work and funding of the CDC tobacco work.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —

Contacted: Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); White House Office; U.S. Agency for International Development (USAID); State, Dept of (DOS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Labor, Dept of (DOL); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES

Tobacco TOB

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control as considered in House and Senate, FY18 and The FY19 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273. Issues regarding flavors in tobacco products including e-cigarettes and cigars respecting S.3319, the SAFE Kids Act, and development of similar legislation. Issues relating to trade and investment agreements and tobacco. Issues regarding CDC future funding and work related to tobacco.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE New —

Contacted: Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); State, Dept of (DOS); Environmental Protection Agency (EPA); SENATE; Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); Veterans Affairs, Dept of (VA); Labor, Dept of (DOL); Natl Institutes of Health (NIH); White House Office

Bills named: S. 2100 (115th), H.R. 564 (115th), H.R. 1136 (115th), S. 3319 (115th), S. 294 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.